FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy

Cancer Imaging

Volumn 15, Issue 1, 2015, Pages

  Beauregard, Jean Mathieu ^a,b   Blouin, Annie Claude ^a,b   Fradet, Vincent ^a,b   Caron, André ^a,b   Fradet, Yves ^a,b   Lemay, Claude ^c   Lacombe, Louis ^a,b   Dujardin, Thierry ^a,b   Tiguert, Rabi ^a,b   Rimac, Goran ^a,b   Bouchard, Frédérick ^a,b   Pouliot, Frédéric ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c Centre Hospitalier du Christ Roi   (Canada)

Author keywords

FDG PET CT; High grade; Prognostic stratification; Prostate cancer; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE PERIOD; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; ADENOCARCINOMA; AGED; BONE; LYMPH NODE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; PROSTATE TUMOR; X-RAY COMPUTED TOMOGRAPHY;

ADENOCARCINOMA; AGED; BONE AND BONES; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84941266380     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1186/s40644-015-0038-0     Document Type: Article

References (28)

1. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 2003;21:2163-72.
2. Pouliot F, Johnson M, Wu L. Non-invasive molecular imaging of prostate cancer lymph node metastasis. Trends Mol Med. 2009;15:254-62.
3. 11C-choline. J Nucl Med. 2011;52:81-9.
4. 99mTc-MDP bone scan in progressing metastatic prostate cancer. Clin Cancer Res. 2010;16:6093-9.
5. 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med. 2013;54:1195-201.
6. Salminen E, Hogg A, Binns D, Frydenberg M, Hicks RJ. Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. Acta Oncol. 2002;41:425-9.
7. Jana S, Blaufox MD. Nuclear medicine studies of the prostate, testes, and bladder. Semin Nucl Med. 2006;36:51-72.
8. 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer. Urol Int. 2003;70:311-5.
9. 18F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer. J Med Imaging Radiat Oncol. 2010;54:325-32.
10. Stewart GD, Gray K, Pennington CJ, Edwards DR, Riddick ACP, Ross JA, et al. Analysis of hypoxia-associated gene expression in prostate cancer: lysyl oxidase and glucose transporter-1 expression correlate with Gleason score. Oncol Rep. 2008;20:1561-7.
11. Effert P, Beniers AJ, Tamimi Y, Handt S, Jakse G. Expression of glucose transporter 1 (Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma. Anticancer Res. 2004;24:3057-63.
12. Punnen S, Freedland SJ, Presti Jr JC, Aronson WJ, Terris MK, Kane CJ, et al. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy. Eur Urol. 2013;65:1171-7.
13. Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. 2011;117:5039-46.
14. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999;17:1499-507.
15. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ, Dotan ZA, DiBlasio CJ, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2005;23:7005-12.
16. Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013;190:419-26.
17. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61-71.
18. Hövels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63:387-95.
19. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis. 2012;15:45-55.
20. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology. 2010;254:925-33.
21. 11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction. J Nucl Med. 2013;54:699-706.
22. Briganti A, Karmes JR, Da Pozzo LF, Cozzarini C, Gallina A, Suardi N, et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol. 2009;55:261-70.
23. Briganti A, Blute ML, Eastham JH, Graefen M, Heidenreich A, Karnes JR, et al. Pelvic lymph node dissection in prostate cancer. Eur Urol. 2009;55:1251-65.
24. Kitajima K, Murphy RC, Nathan MA. PET/CT for imaging prostate cancer: an update. Ann Nucl Med. 2013;27:581-91.
25. 11C-choline PET/CT with histopathologic step-section analysis. J Nucl Med. 2005;46:1642-9.
26. 11C] choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging. 2008;35:1065-73.
27. Kotb AF, Tanguay S, Luz MA, Kassouf W, Aprikian AG. Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance. Prostate Cancer Prostatic Dis. 2011;14:53-7.
28. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA. 1999;281:1395-400.